𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combined modality therapy for locally advanced non-small cell lung carcinoma

✍ Scribed by D. Recine; K. Rowland; S. Reddy; M. S. Lee; P. Bonomi; S. Taylor IV; L. P. Faber; W. Warren; C. F. Kittle; F. R. Hendrickson


Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
691 KB
Volume
66
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Multi-modality treatment consisting of cisplatin, VP-16, and 5-fluorouracil chemotherapy given concomitantly with external beam radiation was used to treat 64 patients with locally advanced Stage I11 non-small cell lung carcinoma. This regimen was used in a preoperative fashion for four cycles in patients considered surgically resectable and with curative intent for six cycles in the remainder of patients. The clinical response rate for the entire group was 84% and the overall local control rate was 74%. The median survival was 13 months with a median follow-up for live patients of 19 months. The actuarial %year survival and diseasefree survival rates were 30% and 23%, respectively. Histologic complete response was 39% and appeared to predict for survival. The 3-year actuarial survival and disease-free survival rates for 23 resected patients were 69% and 45%, respectively, with the complete histologic responders having a disease-free survival of 78%. The pattern of first recurrence did not appear to differ by histology or presence of lymph nodes in this subset of patients. The actuarial %year survival and disease-free survival rates for inoperable patients receiving six cycles of treatment were 18% and 23%, respectively. The local control was 67% with the majority of these patients having Stage IIIB disease. The Mountain International staging system appeared to predict for operability, local recurrence, and survival. This concomitant treatment regimen is feasible, with the major toxicities being leukopenia, nausea, and vomiting. Cancer 66:2270-2278,1990, ON-SMALL CELL LUNG cancer presents as locally ad-N vanced non-metastatic disease in approximately one-third of all cases. A small subset of these patients have disease amenable to surgical resection, although survival rates are poor when compared to Stage I and I1 disease.' Preoperative radiation has not shown any survival benefit in two large collaborative ~tudies,'~~ although there is some evidence that resected Stage I11 patients may have increased s~rvival.~ Patients not eligible for surgery are usually treated with external beam radiation alone with


πŸ“œ SIMILAR VOLUMES


Results of combined-modality therapy for
✍ Steven E. Schild; Philip J. Stella; Burke J. Brooks; Sumithra Mandrekar; James A πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 2 views

## Abstract ## BACKGROUND A Phase III trial was conducted by the North Central Cancer Treatment Group to determine whether chemotherapy (etoposide and cisplatin) plus either twice‐daily radiotherapy (BIDRT) or once‐daily radiotherapy (QDRT) resulted in a better outcome for patients with limited‐st

A 10-year experience with combined modal
✍ Renee H. Jacobs; Alice Greenburg; Jacob D. Bitran; Philip C. Hoffman; Kathy S. A πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons 🌐 English βš– 693 KB

During the past 10 years, 240 patients with Stage I11 small cell lung carcinoma (SCLC) were treated with one of five chemotherapy programs plus thoracic irradiation. In addition, prophylactic cranial irradiation was administered concurrently with thoracic irradiation to 194 patients receiving CAML-H

Combined modality therapy for stage IIIM
✍ Patricia J. Madej; Jacob D. Bitran; Harvey M. Golomb; Philip G. Hoffman Jr; Thom πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 720 KB

Between 1975 and 1980, 101 patients with inoperable Stage IIIMO non-small cell lung carcinoma were entered into combined radiotherapy and chemotherapy trials at Michael Reese Hospital and University of Chicago Hospital. Sixty-four percent of the patients responded. Median survival for all patients w